Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (<b>A</b>, <b>C</b>, and <b>E</b>) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autore principale: Kristoffer Staal Rohrberg (15009138) (author)
Altri autori: Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
Pubblicazione: 2025
Soggetti:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunology
Antibodies/immunoconjugates
Lung Cancer
Melanoma
Ovarian Cancer
Sarcomas
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
Descrizione
Riassunto:<p>Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (<b>A</b>, <b>C</b>, and <b>E</b>) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best overall response (<b>B</b>, <b>D</b>, and <b>F</b>). <b>A</b> and <b>B,</b> Cohort 1 (Q3W): NSCLC with sensitizing <i>EGFR</i> mutations and/or mutations targeted by third-generation TKIs (<i>n</i> = 22). <b>C</b> and <b>D,</b> Cohort 2 (2.2 mg/kg Q3W): NSCLC without activating <i>EGFR</i> mutations or <i>ALK</i> rearrangements (<i>n</i> = 55). <b>E</b> and <b>F,</b> Cohort 8 (3Q4W): NSCLC without activating <i>EGFR</i> mutations or <i>ALK</i> rearrangements (<i>n</i> = 26). NE, not evaluable; PD, progressive disease; PR, partial response.</p>

Documenti analoghi